摘要
目的观察沙库巴曲缬沙坦钠治疗高血压合并阵发心房颤动患者的疗效及对患者心房晚电位的影响。方法选择2021年1—8月在邢台市第三医院心内科门诊就诊或住院的高血压合并阵发性心房颤动患者60例,采用随机数字表法分为观察组和对照组,每组30例。对照组患者给予厄贝沙坦治疗,观察组患者给予沙库巴曲缬沙坦钠治疗,2组患者均治疗6个月。记录2组患者治疗前后的左心房容积指数(LAVI)、左心房内径(LAD)、P波滤波后时限(Ad)及P波终末20 ms电压均方根(LP20),随访2组患者心房颤动发作情况。结果治疗6个月后,2组患者LAVI及LAD均明显降低,且观察组LAD较对照组低(P<0.05或P<0.01),但2组LAVI比较差异无统计学意义(P>0.05)。与治疗的前3个月比较,治疗的后3个月2组的心房颤动发作频度及发作持续时间均明显降低(P<0.01),但2组治疗的前3个月房颤发作频度及发作持续时间比较差异无统计学意义(P>0.05),治疗的后3个月,2组心房颤动发作频度差异无统计学意义(P>0.05),观察组心房颤动持续时间短于对照组(P<0.05)。与治疗前比较,治疗6个月后,2组患者的Ad明显降低,LP20明显升高,且观察组降低/升高幅度大于对照组(P<0.05或P<0.01)。结论沙库巴曲缬沙坦钠治疗高血压合并阵发心房颤动可明显改善患者LAD及心房晚电位指标,缩短心房颤动发作持续时间。
Objective To observe the effect of sacubitril valsartan sodium in the treatment of hypertensive patients with paroxysmal atrial fibrillation and its impact on atrial late potential.Methods Sixty patients with hypertension and paroxysmal atrial fibrillation who were treated or hospitalized at the Cardiology Department of Xingtai Third Hospital from January to August 2021 were selected,they were divided into observation group and control group using random number table method,with 30 cases in each group.Patients in the control group were treated with irbesartan,while patients in the observation group were treated with sacubitril valsartan sodium,both groups of patients were treated for 6 months.Recorded the left atrial volume index(LAVI),left atrial diameter(LAD),P-wave filtered time limit(Ad)and P-wave terminal 20 ms root mean square voltage(LP20)of two groups of patients before and after treatment.Followed up the incidence of atrial fibrillation in both groups of patients.Results After 6 months of treatment,the LAVI and LAD in both groups of patients were significantly reduced,and the LAD in the observation group was lower than that in the control group(P<0.05 or P<0.01).However,there was no statistically significant difference in LAVI between the two groups(P>0.05).Compared with the first three months of treatment,the frequency and duration of atrial fibrillation attacks in the two groups were significantly reduced in the latter three months of treatment(P<0.01).However,there was no statistically significant difference in the frequency and duration of atrial fibrillation attacks in the first three months of treatment between the two groups(P>0.05).There was no statistically significant difference in the frequency of atrial fibrillation attacks between the two groups in the latter three months of treatment(P>0.05),the duration of atrial fibrillation in the observation group was shorter than that in the control group(P<0.05).Compared with before treatment,after 6 months of treatment,the Ad of the two groups of pat
作者
李振莲
史苏娜
王秀玲
杨柳
任振芳
朱凌凌
彭红兵
LI Zhenlian;SHI Suna;WANG Xiuling;YANG Liu;REN Zhenfang;ZHU Lingling;PENG Hongbing(Department of Cardiology,Xingtai Third Hospital,Hebei Province,Xingtai 054000,China;不详)
出处
《临床合理用药杂志》
2023年第16期6-9,共4页
Chinese Journal of Clinical Rational Drug Use
基金
邢台市科学技术局项目(2021ZC107)。
关键词
高血压
阵发性心房颤动
沙库巴曲缬沙坦钠
左心房容积指数
心房晚电位
Hypertension
Paroxysmal atrial fibrillation
Sacubitril valsartan sodium
Left atrial volume index
Atrial late potential
